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Cyclophosphamide’s lack of hematopoietic stem cell toxicity and its unique effects on the immune system
have prompted several investigators to explore its potential for the prevention of graft-versus-host disease
(GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together
with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell
depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced
encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a
review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and
summarize the clinical data on its use for the prevention of GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although considerable advances have been made in HLA
matching and donor selection, graft-versus-host disease
(GVHD) remains a major impediment to the development
andwidespread applicability of allogeneic blood andmarrow
transplantation [1-3]. Despite the routine use of prophylactic
therapies, acute GVHD complicates 40% to 50% of transplants,
whereas chronic GVHD is encountered in 10% to 80% of cases
[1-3]. The detrimental effect of current prophylactic regi-
mens on immune reconstitution and the potential to abolish
graft-versus-disease (GVD) effect have provided additional
impetus to develop alternative regimens.
In 1963, based on personal work and that of others,
Berenbaum [4] reported that skin allografts in mice have
better survival after the administration of a single dose of
cyclophosphamide 1 to 3 days after grafting. Subsequent
animal experiments and clinical trials enhanced our under-
standing of the immune modulatory effects of cyclophos-
phamide and established a platform for innovation and
progress in the ﬁeld of transplantation. Here, we review the
data on the use of post-transplant high-dose cyclophospha-
mide for the prevention of GVHD.edgments on page 610.
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Cyclophosphamide is an alkylating agent of the nitrogen
mustard category. It has been in use formany years and has an
excellent toxicity proﬁle [5]. Cyclophosphamide is oxidatively
metabolized by the hepatic cytochrome P450 into 2 powerful
metabolites, phosphoramide mustard and acrolein, and pre-
vents cell division by crosslinking DNA strands. Although the
alkylating effect of the active metabolites occurs throughout
the cell cycle, it is most pronounced during the G1 and S
phases of cell division [6]. Rapidly proliferating cells subjected
to DNA crosslinking are more susceptible to cyclophospha-
mide because of their reduced ability to replicate damaged
DNA. Conversely, hematopoietic stem cells that are rich in
aldehyde dehydrogenase, the enzyme required for the
conversion of phosphoramide mustard into the inactive
metabolite carboxycyclophosphamide, are resistant to cyclo-
phosphamide. Consequently, cyclophosphamide can be
administered after allogeneic hematopoietic cell transplant
without impairing engraftment [7].
A fundamental difference of the effect of cyclophospha-
mide on T cells in contrast to other immunosuppressive
agents is its ability to induce apoptosis. Comparing the
effects of different drugs on human peripheral blood T cells,
cytotoxic cell lines, and Jurkat T cells, Strauss et al. [8] found
that only cyclophosphamide (and methotrexate) triggered
cell death. All other drugs, including steroids, calcineurin
inhibitors, sirolimus, and mycophenolate mofetil (MMF)
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cyclophosphamide up-regulated Fas (CD95) expression,
triggering activation-induced cell death within 6 days of
activation. None of the other drugs affected CD95 expression.
Early animal experiments identiﬁed cyclophosphamide as
the most effective drug to suppress antibody production in
response to bacterial vaccines [9]. In addition, unlike other
antimitotics, cyclophosphamide did not need to be used at
low doses over prolonged periods of time [4,9]. In organ
transplantation, pivotal experiments showed that cyclo-
phosphamide administered intraperitoneally in single high
dose early after skin allografts in mice was sufﬁcient to delay
graft rejection across MHC mismatches. The timing of
cyclophosphamide administration was critical [4,10].
Although administration of cyclophosphamide to mice
before or simultaneously with allogeneic stimuli suppressed
antibody production, tolerance was not induced. The
maximal effect in improving graft survival was observed
when cyclophosphamide was given between grafting and
day 4 afterward [4,10]. Furthermore, although cyclophos-
phamide only delayed graft rejection in MCH mismatches, it
induced deﬁnitive tolerance across minor histocompatibility
mismatches [11,12].
Based on earlier experiments performed by Nirmul et al.
[11,12], Mayumi et al. [13] established a “cells-followed-by-
cyclophosphamide” scheme in which administration of
allogeneic spleen cells followed by cyclophosphamide
administration 2 days thereafter induced tolerance to allo-
grafts in different mouse models. Several studies have
examined the mechanism of action of cyclophosphamide.
Vb6-bearing T cells directed to minor lymphocyte stimu-
lating-1a (Mls-1a) were examined in a skin allograft experi-
ment in which BALB/c mouse recipient (Mls-1b) were
rendered tolerant to DBA/2 mouse donor (Mls-1a) with
donor spleen cells and cyclophosphamide [14]. In the early
phase, the donor-reactive proliferative CD4þ-Vb6 T cells in
the lymph nodes were destroyed (clonal destruction),
whereas the resting CD8þ-Vb6þ T cells were spared.
Furthermore, neither immature CD4þ-Vb6 nor immature
CD8þ-Vb6 present in the thymus on day 14 were detectable
by day 35 (clonal deletion). In contrast to clonal destruction,
clonal deletion was long-lasting. These ﬁndings were sup-
ported by similar experiments based on different models
[15-17]. In one similar study, the complete disappearance of
CD4þ cells in the periphery was delayed until thymus
depletion occurred [18].
In hematopoietic stem cell transplantation, the same 2
mechanisms of action of cyclophosphamide were conﬁrmed
to prevent GVHD by affecting host-reactive cells. When AKR/
J-derived Thy-1.1 cells expressing Vb3 directed against Mls-2a
were examined in a model using a CH3/He mouse recipient
(H-2k, Mls-1b, Mls-2a) and AKR/J mouse donor (H-2k, Mls-1a,
Mls-2b), cyclophosphamide similarly induced early clonal
destruction of donor cells followed by clonal deletion of host-
reactive cells [19]. These results were supported by the
ﬁndings by Huyan et al. [20], who examined the effect of
intraperitoneal administration of cyclophosphamide on pe-
ripheral blood lymphocyte counts in mice. Although 50 mg/
kg produced no signiﬁcant effect, higher doses induced a
dose-dependent decrease in CD4þ cells. The decrease began
on day þ1 and reached nadir on day þ4. After a transient
rebound, cell numbers decreased again after day þ10. The
same pattern was observed for B lymphocytes. In contrast,
CD8þ cells increased on day 4 [20]. Conceivably, the early
decrease in CD4þ but not CD8þ counts was due to clonaldestruction, whereas the later decrease in CD4þ was sec-
ondary to thymocyte depletion.
Nirmual et al. [11,12] observed that timely administration
of cyclophosphamide prevented sensitization of mice
receiving large dose of donor spleen cells to skin allografts
and prolonged the survival of the grafts. They postulated that
cyclophosphamide acted on proliferating cells triggered into
cycling after contact with antigen. Their hypothesis was
recently conﬁrmed by Ross et al. [21]. In a GVHD mouse
model, donor cells were labeled with proliferation dyes and
traced in syngeneic and allogeneic transplantation experi-
ments. Mice received increasing doses of cyclophosphamide
3 to 4 days after transplantation. In the syngeneic model,
lymphopenia-induced T cell proliferationwas slow, sparing a
large fraction of cells; the nondeleted cells retained func-
tionality. In the allogeneic model, 22 mg/kg cyclophospha-
mide failed to prevent GVHD when antigen-stimulated
T cells undergoing multiple divisions remained present.
However, when the dose was increased to 66 mg/kg, GVHD
was alleviated, and only the ﬁrst 2 to 3 generations of the
rapidly dividing alloreactive T cells remained. Cells under-
going more divisions did not survive, whereas slowly
dividing cells were also preserved. In a different study pub-
lished in abstract form, Cieri et al. [22] studied immune
reconstitution during the ﬁrst month in a series of patients
undergoing T cellereplete peripheral blood haploidentical
transplantation. GVHD prophylaxis consisted of post-
transplant cyclophosphamide combined with MMF and
sirolimus. Although proliferating alloreactive T lymphocytes
were abated, memory cells, including stem memory cells
(CD45RAþ, CD62þ, and CD95þ), were increased. The authors
postulated that the increase in stem cell memory cells was
due to differentiation from naïve T cells. These cells escaped
the cyclophosphamide purging effect because of their
delayed proliferation in comparison with the alloreactive
T cells.
Taken together, these ﬁndings suggest that cyclophos-
phamide can prevent GVHD without compromising timely
immune reconstitution. This selective action of cyclophos-
phamide on proliferating T cells has a number of practical
implications. The ﬁrst implication relates to its potential use
in combination with other immunosuppressive agents. For
instance, the concomitant use of drugs that induce T cell
anergy and may prevent cells from cycling might be theo-
retically counterproductive [13]. The addition of such drugs
must rather be delayed. Pan T cell antibodies, on the other
hand, might be synergistic and enhance the deletion of the
relevant T cell clones [13]. On the downside, the selective
action of cyclophosphamide allows memory T cells induced
by prior alloimmunization of the recipient to escape cyclo-
phosphamide and increase the risk of graft failure.
Finally, the effect of cyclophosphamide on regulatory
T cells (Tregs) has been the subject of intense investigation.
Although early animal studies suggested a negative effect of
cyclophosphamide on Tregs, different results were obtained
in human studies. North [23] demonstrated that cyclophos-
phamide can facilitate adoptive immunotherapy of estab-
lished tumors in mice. Although the administration of
cyclophosphamide failed to cause tumor regression, the
combination of cyclophosphamide and spleen cells perma-
nently abolished the tumor. The authors postulated that
“suppressor but not immune T cells” were sensitive to
cyclophosphamide. Similarly, Ghiringhelli et al. [24]
demonstrated that the administration of a single dose of
cyclophosphamide to rats with established tumor depleted
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immunotherapies. A study by Kanakry et al. [25] in humans
receiving myeloablative matched related-donor allogeneic
blood and marrow transplants yielded contrary results. That
study examined the effect of post-transplant cyclophospha-
mide on the different subsets of Tregs. The numbers of naïve
Tregs (CD4þCD45RAþFoxp3þlo) were lower in patients
compared with donors, possibly because of their conversion
to activated Tregs (CD4þCD45RAFoxp3þhi). Indeed, acti-
vated Tregs increased as did the total number of naïve and
activated cells. The authors also demonstrated that the
content of different Tregs in aldehyde dehydrogenase
increased upon activation by allogeneic stimuli, rendering
them resistant to mafosfamide. The cells were conversely
sensitized by aldehyde dehydrogenase inhibition. The same
group studied the role of Tregs in the cyclophosphamide
GVHD prophylactic effect. Using a xenogenic GVHD mouse
model, when peripheral blood mononuclear cell grafts were
depleted of Tregs, the mice had higher GVHD scores and died
earlier. These ﬁndings emphasize the requirement for Tregs
for the optimal effect of cyclophosphamide.
To summarize, Mayumi et al. and Luznik et al. [13,26]
proposed a 3-step scheme to explain the mechanism for
induction of tolerance by post-transplant cyclophospha-
mide. Early, proliferating alloreactive donor and recipient
T cells are selectively destroyed. Next, the increased Tregs
counterbalance the effect of any remaining alloreactive
mechanisms. Finally, the delayed but long-lasting intra-
thymic clonal deletion of anti-host T cells maintains long-
term tolerance.
CLINICAL STUDIES
Haploidentical Transplant
Most early clinical studies on the use of post-transplant
cyclophosphamide for the prevention of GVHD were per-
formed in the setting of haploidentical transplantation
(Table 1). O’Donnell et al. [27] at Johns Hopkins University in
Baltimore conducted a pivotal clinical trial that set the stage
for others. Patients with high-risk hematological malig-
nancies received T cellereplete haploidentical bone marrow
grafts after nonmyeloablative conditioning with 150 mg/m2
ﬂudarabine on days6 to2 and 2-Gy total body irradiation
(TBI) on day 1 followed by 50 mg/kg cyclophosphamide on
day þ3 in combination with MMF from days þ4 to þ35 and
tacrolimus from dayþ4 to at least dayþ50. Two of the ﬁrst 3
patients developed graft rejection. Therefore, 14.5 mg/kg/day
of cyclophosphamide was added on days 6 and 5. Eight of
the 10 subsequent patients achieved sustained engraftment.
Overall, 6 of 13 patients (46%) developed acute GVHD at a
median of 99 days after transplant, with fatal acute GVHD in
1 patient. This study provided proof of principle that post-
transplantation cyclophosphamide can be safely adminis-
tered in the setting of haploidentical hematopoietic stem cell
transplantation, eliminating the need for T celledepleted
mega cell dose grafts [27].
Building on these ﬁndings, Luznik et al. [28] compared
the outcome of patients with advanced hematological ma-
lignancies receiving 1 (n ¼ 28) or 2 (n ¼ 40) doses of
cyclophosphamide administered on days þ3 or þ3 and þ4,
respectively, in addition to MMF and tacrolimus. All 68
patients underwent nonmyeloablative conditioning as
described above, followed by T cellereplete haploidentical
bone marrow grafts. Nine of 66 assessable patients (13%)
had graft failure. The remainder engrafted with a median
time to neutrophil recovery of 15 days and to plateletrecovery of 24 days. The cumulative incidence of treatment-
related mortality (TRM) of the entire group was 15%,
whereas the relapse rate at 1 year was 51%. The 2-year
overall survival (OS) and event-free survival (EFS) rates
were 36 and 26%, respectively. Thirty-four percent of
patients developed acute GVHD grades II to IV and 6%
developed grades III to IV. The only difference between the
2 groups was a trend toward a lower incidence of extensive
chronic GVHD (5% versus 25%; P¼ .05) for patients receiving
2 doses of cyclophosphamide. The robust suppression of
alloreactivity by post-transplant cyclophosphamide was
further supported by a retrospective analysis of 3 similar
trials that revealed the number of HLA mismatches at A, B,
C, and DRB1 loci had no impact on EFS and the incidence of
grades II to IV acute GVHD [29].
More recently, Munchel et al. [30] reported on behalf of
the Johns Hopkins University group the results of a large
phase II study enrolling 210 patient with advanced hema-
tological malignancies. Patients received haploidentical bone
marrow transplants using the group’s original non-
myeloablative conditioning regimen and GVHD prophylaxis
protocol. Eighty-seven percent of patients experienced
sustained engraftment. The incidence of 5-year TRM was
18%. The incidence of disease relapse was 55%, with EFS and
OS rates of 35% and 27% respectively. The incidence of acute
grades II to IV GVHD and chronic GVHD was 27% and 13%,
respectively, conﬁrming the notably low incidence of chronic
GVHD.
The Bone Marrow Transplant Clinical Trials Network
sponsored a trial treating in parallel 2 groups of patients at
two different centers. The ﬁrst group received haploidentical
blood and marrow transplantation with post-transplant
cyclophosphamide, and the second group received umbili-
cal cord blood transplant in patients with high-risk hema-
tological malignancies [31]. The ﬁrst group received the same
nonmyeloablative conditioning regimen used by the Johns
Hopkins University group. The second group received a
conditioning regimen combining ﬂudarabine 160 mg/m2,
cyclophosphamide 50 mg/kg, and TBI 2 Gy. The OS and EFS
rates were 62% and 48%, respectively, for the haploidentical
transplants and 54% and 46%, respectively, for the group
receiving cord blood transplant. The incidence of acute GVHD
grades II to IV and III to IV was 32% and 0%, respectively, for
the ﬁrst group and 40% and 21%, respectively, for the second
group. The 1-year rate of chronic GVHD was 13% and 25%,
respectively. The authors concluded that both approaches
were useful and provided outcomes similar to the outcome
of patients receiving reduced-intensity conditioning trans-
plants from matched related or matched unrelated donors.
This conclusion is consistent with Bashey et al.’s [32] retro-
spective analysis of 53 patients receiving haploidentical bone
marrow or peripheral blood stem cells with post-transplant
cyclophosphamide in comparison with patients treated at
the same center with matched related (n ¼ 117) or unrelated
(n ¼ 101) donor transplants receiving standard GVHD pro-
phylaxis. This latter study also demonstrated no difference in
TRM, relapse, or survival rates, with a similar incidence of
GVHD.
Although most initial studies focused on the use of bone
marrow, several recent studies explored the role of post-
transplant cyclophosphamide in permitting the use of pe-
ripheral blood instead of bone marrow and to omit the need
for mega cell dose grafts originally introduced to induce
immune tolerance [33]. Solomon et al. [34] studied 20
patients with hematological malignancies, 11 of whom had
Table 1
Summary of the Published Studies Using Post-Transplant Cyclophosphamide for Prophylaxis of GVHD
Reference
First author
Type of Study No. of
Patients
Median
Patient
Age (yr)
Conditioning
Regimen
Donor and
Graft Source
Graft Failure GVHD Prophylaxis Median
Follow-Up
(mo)
Acute GVHD
Grades II-IV
Chronic GVHD TRM, EFS, OS
27
O’Donnell
Prospective 13 53 JH (ﬁrst 3 patients
without Cy on
days e6 and e5)
HID-BM 4 (30%)
(2 of the ﬁrst
3 patients)
Cy50  1 þ MMF þ TAC 6.4 46% NR 18%, 38%, 46%
28
Luznik
Prospective 68 Range .5-70 JH HID-BM 9 (14%) Cy50  1 (28) or Cy50
 2 (40) þ MMF þ TAC
24 34% Cy50  1: 25%
Cy50  2: 5%
P ¼ .05
15%, 26%, 36%
29
Kasamon
Retrospective
from 3 trials
(67 patients were
included
in reference 23)
185 50 JH HID-BM 29 (16%) Cy50  1 (48) or Cy50
 2 (137) þ MMF þ TAC
6 31% 15% 15%, 35% at 1 yr, NR
30
Munchel
Prospective 210 52 Flu þ Cy þ TBI (2)
NMA
HID-BM Of 204: 27
(13%)
Cy50  2 þ MMF þ TAC 27% 13% 18%, 32% at 3 y,
41% at 3 yr
31
Brunstein
Comparison of
2 separate
prospective
conducted in
parallel
100 HID: 48
CB: 58
HID: JH
CB: Flu þ Cy þ TBI
(2 Gy)
HID-BM (in 1 study)
CB (in the second
study)
HID: 1 (2%)
CB: 6 (12%)
HID: Cy50  2 þ
MMF þ TAC
CB: MMF þ CSA
12 HID: 32%
CB: 40%
HID: 13%
CB: 25%
HID: 7%, 48%
at 1 y, 62% at 1 yr
CB: 24%, 46%
at 1 y, 54% at 1 yr
Relapse
HID: 45% CB: 31%
32
Bashey
Retrospective
comparison
between 2
groups of patients
271 HID: 46
MRD: 50
MUD: 51
HID: JH (35) or Flu þ
Bu þ Cy (MA) (18)
MRD: MA (70) or
NMA (47)
MUD: MA (47) or
NMA (54)
HID: BM (32),
HID: PB(21)
MRD and MUD:
PB (most)
NR HID: Cy50  2 þ
MMF þ TAC
24 HID: 30%
MRD: 27%
MUD: 39%
HID: 4%
MRD: 11%
MUD: 12%
P ¼ .05 in favor
of HID vs. MRD
or MUD
*all were severe
HID: 7%, 60% at
2 y, 64% at 2 yr
MRD: 13%, 53%
at 2 y, 76% at 2 yr
MUD: 16%, 52% at
2 y, 67% at 2 yr
Relapse
HID: 33% MRD
and MUD: 34%
34
Solomon
Prospective 20 44 Flu þ Bu þ Cy (MA) HID-PB 0 Cy50  2 þ MMF þ TAC 20 30% 35% 10%, 50% at 1 yr, 69%
at 1 yr
35
Bhamidipati
Abstract
Retrospective 18 41 JH HID-PB 2 (11%) Cy50  2 þ MMF þ
TAC (16)
Cy50  2 þ MTX þ
TAC (2)
8.4 40.7% 8% 17%, 53% at 1 yr, 62%
at 1 yr
36
Ciurea
Retrospective
comparison
between 2 groups
of patients
65 TCR: 45
TCD: 36
TCR: MA (26) or
NMA (6)
TCD: MA
TCR: HID-BM (31)
HID-PB (1)
TCD: HID-PB
TCR 6%
TCD: 19%
TCR: Cy50  2 þ
MMF þ TAC
TCD: ATG
TCR: 11
TCD: 48
TCR: 20%
TCD: 11%
TCR: 7%
TCD: 18%
P ¼ .03
TCR: 16%, 50% at
1 yr, 64% at 1 yr
TCD: 42%, 21%
at 1 yr, 30% at 1 yr
P ¼ .02
37
Castagna
Retrospective
comparison
between 2 groups
of patients
69 HID-BM: 44
HID-PB: 54
JH HID-BM (46)
HID-PB (23)
Reported as
similar
between
the 2 groups
Cy50  2 þ MMF þ
CSA or TAC
18 HID-BM: 25%
HID-PB: 33%
HID-BM: 13%
HID-PB: 13%
2 y HID: BM 22%
PB 12%, reported as
similar between
2 groups (62%),
reported as similar
between 2 groups
(68%)
38
Gayoso
Abstract
Retrospective
review:
Hodgkin disease
29 31 Flu þ Cy þ TBI 2
(NMA) or
Flu þ Cy þ Bu (NMA)
HID-BM (15)
HID-PB (14)
NR Cy50  2 þ MMF þ
CSA or TAC
9 25% 16% 17% 59%, NR
Relapse 21%
(continued on next page)
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loablative conditioning regimen followed by T cellereplete
peripheral blood stem cells from haploidentical donors. The
maximal CD34 cell dose was 5  106/kg. GVHD prophylaxis
consisted of cyclophosphamide 50 mg/kg on days þ3
andþ4 followed by tacrolimus andMMF starting on dayþ5.
All patients engrafted. One-year OS and EFS rates were 69%
and 50%, respectively, for the entire group and 88% and 67%
for the 9 patients in remission at the time of transplant. The
overall incidences of grades II to IV and grades III to IV acute
GVHD were 30% and 10%, respectively. At a median follow-
up of 20 months, the incidence of chronic GVHD was 35%
(5% severe). These results were substantiated by Bhamidi-
pati et al. [35] for nonmyeloablative conditioning. The
incidence of extensive chronic GVHD in this study was also
5%.
Furthermore, 2 additional studies reported the results of
retrospective comparisons between haploidentical trans-
plants using bone marrow or peripheral blood as the source
of grafts. First, Ciurea et al. [36] analyzed 65 consecutive
patients with hematological malignancies receiving
T cellereplete peripheral blood stem cell transplants (n¼ 32,
TCR group) as opposed to T celledeplete bone marrow
transplants (n ¼ 33, TCD group). Both groups received the
same conditioning regimen combining ﬂudarabine,
melphalan, and thiotepa. The ﬁrst group was administered
post-transplant cyclophosphamide along with tacrolimus
and MMF for GVHD prophylaxis. For the TCD group, the only
GVHD prophylaxis consisted of 6 mg/kg rabbit antithymo-
cyte globulin. There was no difference in engraftment be-
tween the 2 groups. However, TRM was lower in the TCR
group (16% versus 42%; P ¼ .02). OS and EFS rates were 64%
versus 30% (P ¼ .02) and 50% versus 21% (P ¼ .02), respec-
tively, in favor of the TCR group. There was no signiﬁcant
difference in the incidence of acute GVHD grades II to IV (20%
in the TCR versus 11% in the TCD group; P ¼ .2), whereas
chronic GVHD was less frequent in the TRC group (7% versus
18%; P ¼ .03). Recovery of CD4þ and CD8þ cells was signiﬁ-
cantly faster in the TCR transplant patients. This was also true
for naïve and memory T cells and translated into a lower
incidence of viral and fungal infections. The authors
concluded that the outcome of TCR transplants with post-
transplant cyclophosphamide was superior to that of TCD
transplants. In the second study, Castagna et al. [37]
compared 2 groups receiving T cellereplete grafts. The ﬁrst
group received bone marrow grafts (n ¼ 46), whereas the
second group received peripheral blood grafts (n ¼ 23). No
differences in OS or EFS were observed. The incidences of
acute and chronic GVHD were also statistically similar.
Enrolling only patients with relapsed or refractory
Hodgkin disease, Gayoso et al. [38] presented the outcome of
29 patients conditioned with a combination of ﬂudarabine,
cyclophosphamide, and either busulfan (6.4 mg/kg) or TBI
2 Gy. Most patients (72%) had active disease at the time of
transplant. With a short follow-up, 59% of patients were in
complete remission. The rates of acute and chronic GVHD
were comparable with those reported in other studies.
Finally, the John Hopkins University group reported the
outcome of haploidentical transplantation in nonmalignant
illnesses using their original regimen [39]. Most patients in
this study had sickle cell disease. Six of 14 patients (43%) had
graft failure. The incidence of acute and chronic GVHD was
very low, with only 1 patient developing skin GVHD but
requiring no therapy. However, the low incidence of GVHD
might be due in part to the high rate of graft failure. At a
Table 2
Summary of Selected Registered Trials Including Post-Transplant Cyclophosphamide for GVHD Prevention
Study Identiﬁcation Study Type Intervention Responsible Party
NCT01749111 Phase III randomized PTCy versus MTX and CNI for GVHD prevention in
MRD and MUD transplants
Paulo V. Campregher, MD
Hospital Israelita Albert Einstein
NCT01860170 Phase I PTCy and bortezomib for GVHD prevention in MRD
and MUD transplants
A. Samer Al-Homsi, MD
Spectrum Health Hospitals
NCT01349101 Phase II PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical and MUD transplants
John L. Wagner, MD
Thomas Jefferson University
NCT02065154 Phase II PTCy for GVHD prevention in MUD andmismatched
UD transplants
Racquel Innis-Shelton, MD
University of Alabama at Birmingham
NCT00622895 Phase I/II PYCy, MMF, and tacrolimus for GVHD
prevention in MRD and MUD transplants in severe
systemic sclerosis
George Georges, MD
Fred Hutchinson Cancer Research Center
NCT01350232 PTCy for GVHD prevention in haploidentical and
MRD transplants for sickle cell disease.
Alloimmunized patients receive rituximab and
bortezomib with or without plasma exchange.
Patients receive donor lymphocyte infusion
followed by PTCy followed by CD34 selected graft.
Joanne Flilicko-O’Hara, MD
Thomas Jefferson University
NCT02167958 Phase I PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants using
peripheral blood
Raﬁc Farah, MD
University of Pittsburgh
NCT01374841 Phase II PTCy, MMF, and tacrolimus for GVHD prevention in
haploidentical transplants
Rocco Pastano, MD
European Institute of Oncology
NCT01028716 Phase II PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants using
peripheral blood
Rachel Salit, MD
Fred Hutchinson Cancer Research Center
NCT02053545 Phase I/II PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants
Reggie E. Duerst, MD
Children’s Hospital of Chicago
NCT01435447 Phase II PTCy for GVHD prevention in transplants for adult
ALL
Jiong Hu, MD
Shanghai Jiao Tong University School
of Medicine
NCT01707004 Phase II PTCy, MMF, and tacrolimus for GVHD
prevention in haploidentical transplants
Mark Juckett, MD
University of Wisconsin, Madison
NCT02049580 Phase II PTCy for prevention of GVHD in MRD and MUD
transplants for poor-risk lymphoma
Luca Castgna, MD
Istituto Clinico Humanitas
NCT02208037 Phase II randomized PTCy, MMF, and tacrolimus, MTX,
tacrolimus, and bortezomib, or MTX, tacrolimus,
and maraviroc for prevention of GVHD in MRD,
MUD, and mismatched UD transplants
Javier Bolaños-Meade, MD
Johns Hopkins University
John Koreth, MBBS
Dana-Farber Cancer Institute
Ran Reshef, MD
University of Pennsylvania
NCT01719341 Phase II PTCy for GVHD prevention in haploidentical
transplants
Zi Yi Lim, MB ChB
National University Hospital, Singapore
NCT02169791 Phase II PTCy, tacrolimus, and ixazomib for GVHD
prevention in haploidentical transplants.
Scot Solomon, MD
Northside Hospital
PTCy indicates post-transplant cyclophosphamide; CNI, calcineurin inhibitor; UD, unrelated donor; ALL, acute lymphoblastic leukemia.
A.S. Al-Homsi et al. / Biol Blood Marrow Transplant 21 (2015) 604e611 609median follow-up of almost 2 years, 11 patients were
asymptomatic and 6 were no longer on immunosuppressive
therapy. The high rate of graft failure in hemoglobinopathies
is not unique to this study. This can be explained by the lack
of prior cytotoxic chemotherapy or decreased sensitivity to
cyclophosphamide of effector T cells induced by alloimmu-
nization secondary tomultiple transfusions. The authors also
speculated that ABO incompatibility may be a factor [39].
Intensifying the degree of immunosuppression of the con-
ditioning regimen and performing transplantation earlier in
the course of disease before alloimmunization occurs can
conceivably overcome these barriers.
Matched Related and Unrelated Transplant
Having established the role of post-transplant cyclo-
phosphamide in the setting of haploidentical trans-
plantation, the Johns Hopkins University group examined its
role in matched related and unrelated transplants as the only
GVHD prophylactic therapy. After performing a pilot study,
Luznik et al. [40] reported the results of a large cohort of
patients with advanced hematological malignancies who
received myeloablative conditioning followed by grafts frommatched related (n ¼ 78) or unrelated (n ¼ 39) donors.
Overall, TRM was 17%. OS and EFS rates at 2 years were 55%
and 39%, respectively, for the entire group and 63% and 54%,
respectively, for patients with no evidence of disease at the
time of transplantation. Acute GVHD grades II to IV occurred
in 43% of patients. The incidence of chronic GVHD was again
low at 10%.
Kanakry et al. [41] performed a similar multi-institutional
study using a combination of ﬂudarabine and busulfan at
myeloablative doses as the conditioning regimen. The source
of the grafts was T cellereplete bone marrow from matched
related (n ¼ 45) or unrelated (n ¼ 47) donors. Twenty-ﬁve
patients had active hematological malignancy at the time
of transplantation. Cyclophosphamide was the sole GVHD
prophylaxis. With a median follow-up of 1.6 years, the TRM
was 16%, and OS and EFS rates were 62% and 67%, respec-
tively. The incidence of grades II to IV and III to IV acute GVHD
was 51% and 15%, respectively, whereas the incidence of
chronic GVHD was again low at 14%.
Finally, a matched controlled analysis of 2 groups
receiving either post-transplant cyclophosphamide or
tacrolimus and methotrexate as GVHD prophylaxis after
A.S. Al-Homsi et al. / Biol Blood Marrow Transplant 21 (2015) 604e611610matched related and unrelated donor reduced-intensity
transplants was reported in an abstract [42]. The TRM was
36% and 16% (P ¼ .1), respectively; progression-free survival
was 22% and 33% (P ¼ .4), respectively; and OS was 26% and
46% (P ¼ .08), respectively. The incidence of acute GVHD
grades II to IV was 46% and 19% (P ¼ .02), respectively, and
that of chronic GVHD was 14% and 21% (P ¼ .7), respectively.
The unfavorable outcomes of patients receiving post-
transplant cyclophosphamide can be explained by the
surprisingly high TRM. In addition, the incidence of acute
GVHD in the control group was lower than traditionally
encountered.ONGOING AND FUTURE CLINICAL TRIALS
A number of trials have been initiated to conﬁrm the
current data and also to compare haploidentical transplant
made practical by post-transplant cyclophosphamide with
matched sibling, matched unrelated, and cord blood
transplants. Conﬁrmatory studies examining the role
of cyclophosphamide are also underway in matched
related and unrelated donor transplants. In this setting,
cyclophosphamide is an appealing platform to be used in
combination with other agents. The options include combi-
nations with calcineurin and m-TOR inhibitors or with pan
T cell antibodies. Other combinations using agents that affect
other cellular components involved in GVHD pathogenesis,
such as dendritic cells or cytokines, are attractive. The com-
binations with ruxolitinib, a potent suppressor of dendritic
cells and cytokines [43], or vorinostat, which possesses
anti-GVHD activity, also merit examination [44]. Table 2
summarizes selected registered clinical trials using cyclo-
phosphamide for prevention of GVHD (other trials can be
found at clinicaltrials.gov).CONCLUSION
Cyclophosphamide has a unique mechanism of action. It
selectively destroys rapidly proliferating donor- and host-
alloreactive CD4þ cells while sparing slowly proliferating
cells. This is followed by clonal deletion of immature donor
CD4þ and CD8þ cells in the chimeric thymus. Subsequently,
although the preservation of naïve and activated Tregs
further sustains its immunosuppressive effect, the selective
nature of cyclophosphamide activity permits rapid immune
reconstitution and conceivably preserves the GVD effect. In
haploidentical settings, cyclophosphamide allows the use of
unmanipulated peripheral blood grafts, omitting the need
for any special expertise. In matched related and unrelated
donor transplants, cyclophosphamide alone is active, with a
notably low incidence of chronic GVHD. Conﬁrmatory and
comparative studies are warranted to examine the effect of
such approach on disease relapse and immune reconstitu-
tion. Post-transplant cyclophosphamide also offers the
opportunity to explore its use in conjunction with other
agents in innovative approach.ACKNOWLEDGMENT
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: A.S.A. is a recipient of
research support from Millennium Pharmaceuticals.REFERENCES
1. Welniak LA, Blazar BR, Murohy WJ. Immunobiology of allogeneic he-
matopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:
139-170.2. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine for
prophylaxis of acute graft versus host disease after marrow trans-
plantation for leukemia. N Engl J Med. 1986;314:729-735.
3. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free
immunosuppression using sirolimus and tacrolimus in related and
unrelated donor peripheral blood stem cell transplantation. Blood.
2007;109:3108-3114.
4. Berenbaum MC. Prolongation of homograft survival in mice with single
doses of cyclophosphamide. Nature. 1963;200:84-85.
5. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics
knowledge for personalized medicine. Clin Pharmacol Therap. 2012;92:
414-417.
6. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden
anniversary. Nat Rev Clin Oncol. 2009;6:638-647.
7. Brodsky RA, Petri M, Smith BD, et al. Immunoablative high-dose
cyclophosphamide without stem-cell rescue for refractory, severe
autoimmune disease. Ann Intern Med. 1998;129:1031-1035.
8. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation
of activation and effector function in T cells by immunosuppressive
drugs. Clin Exp Immunol. 2002;128:255-266.
9. Berenbaum MC. The effect of cytotoxic agents on the production of
antibody to T.A.B. vaccine in the mouse. Biochem Pharmacol. 1962;11:
29-44.
10. Berenbaum MC, Brown IN. Dose-response relationships for agents
inhibiting the immune response. Immunology. 1964;7:65-71.
11. Nirmul G, Severin MS, Taub RN. Cyclophosphamide-induced immu-
nologic tolerance to skin homografts. Surg Forum. 1971;22:287-288.
12. Nirmul G, Severin MS, Taub RN. Mechanisms and kinetics of
cyclophosphamide-induced speciﬁc tolerance to skin allografts in mice.
Transplant Proc. 1973;5:675-678.
13. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced
immunological tolerance: an overview. Immunobiology. 1996;195:
129-139.
14. Eto M, Mayumi H, Tomita Y, et al. Sequential mechanisms of
cyclophosphamide-induced skin allograft tolerance including the
intrathymic clonal deletion followed by late breakdown of the clonal
deletion. J Immunol. 1990;145:1303-1310.
15. Matsuura A, Katsuno M, Suzuki Y, et al. Cyclophosphamide-induced
tolerance in fully allogeneic heart transplantation in mice. Cell Immu-
nol. 1994;155:501-507.
16. Kappler JW, Staerz U, White J, Marrack PC. Self-tolerance eliminates T
cell speciﬁc Mls-modiﬁed products of the major histocompatibility
complex. Nature. 1988;332:35-40.
17. MacDonald HR, Schneider R, Lees RK, et al. T-cell Vb use predicts
reactivity and tolerance to Mlsa-encoded antigens. Nature. 1988;332:
40-45.
18. Qin S, Cobbold S, Benjamin R, Waldmann H. Induction of classical
transplantation tolerance in the adult. J Exp Med. 1989;169:779-794.
19. Eto M, Mayumi H, Tomita Y, et al. Speciﬁc destruction of host-reactive
mature T cells of donor origin prevents graft-versus-host disease in
cyclophosphamide-induced tolerant mice. J Immunol. 1991;146:
1402-1409.
20. Huyan XH, Lin YP, Gao T, et al. Immunosuppressive effect of cyclo-
phosphamide on white blood cells and lymphocyte subpopulations
from peripheral blood of Balb/c mice. Int Immunopharmacol. 2011;11:
1293-1297.
21. Ross D, Jones M, Komanduri K, Levy RB. Antigen and lymphopenia-
driven donor T cells are differentially diminished by post-
transplantation administration of cyclophosphamide after
hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;
19:1430-1438.
22. Cieri N, Peccatori J, Oliveiera G, et al. Tracking T cell dynamics in the
ﬁrst month after haploidentical HSCT with post-transplant cyclo-
phosphamide reveals a predominant contribution of memory stem T
cells to the early phase of immune reconstitution. Blood. 2013;122:
4615.
23. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an
established tumor depends on elimination of tumor-induced sup-
pressor T cells. J Exp Med. 1982;155:1063-1074.
24. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4þ CD25þ regulatory T
cells suppress tumor immunity but are sensitive to cyclophosphamide
which allows immunotherapy of established tumors to be curative. Eur
J Immunol. 2004;34:336-344.
25. Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase
expression drives human regulatory T Cell resistance to post-
transplantation cyclophosphamide. Sci Transl Med. 2013;5:1-12.
26. Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophospha-
mide for tolerance induction in HLA-haploidentical BMT. Semin Oncol.
2012;39:683-693.
27. O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow
transplantation from partially HLA-mismatched related donors using
posttransplantation cyclophosphamide. Biol Blood Marrow Transplant.
2002;8:377-386.
28. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone
marrow transplantation for hematologic malignancies using
A.S. Al-Homsi et al. / Biol Blood Marrow Transplant 21 (2015) 604e611 611nonmyeloablative conditioning and high-dose, posttransplantation
cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
29. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative
HLA-haploidentical bone marrow transplantation with high-dose
posttransplantation cyclophosphamide: effect of HLA disparity on
outcome. Biol Blood Marrow Transplant. 2010;16:482-489.
30. Munchel A, Kesserwan C, Symons HJ, et al. Nonmyeloablative HLA-
haploidentical bone marrow transplantation with high dose post-
transplantation cyclophosphamide. Pediatr Rep. 2011;3(Suppl 2):43-47.
31. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor trans-
plantation after reduced intensity conditioning: results of parallel
phase 2 trials using partially HLA-mismatched related bone marrow or
unrelated double umbilical cord blood grafts. Blood. 2011;118:282-288.
32. Bashey A, Zhang X, Sizemore CA, et al. T-cellereplete HLA-haploidentical
hematopoietic transplantation for hematologic malignancies using post-
transplantation cyclophosphamide results in outcomes equivalent to
those of contemporaneous HLA-matched related and unrelated donor
transplantation. J Clin Oncol. 2013;31:1310-1316.
33. Aversa F, Martelli MF, Velardi A. Haploidentical hematopoietic stem
cell transplantation with a megadose T-cell-depleted graft: harnessing
natural and adoptive immunity. Semin Oncol. 2012;39:643-652.
34. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical trans-
plantation using T cell replete peripheral blood stem cells and mye-
loablative conditioning in patients with high-risk hematologic
malignancies who lack conventional donors is well tolerated and
produces excellent relapse-free survival: results of a prospective phase
II trial. Biol Blood Marrow Transplant. 2012;18:1859-1866.
35. Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, et al. Haploidentical
peripheral blood stem cell transplantation using non-myeloablative
conditioning with post-transplant cyclophosphamide regimen is safe
and is associated with very encouraging post-transplant outcomes.
Blood. 2013;122:4532.
36. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes
using a T cell replete graft compared with T cell depleted hap-
loidentical hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. 2012;18:1835-1844.
37. Castagna L, Crocchiolo R, Furst S, et al. Bone marrow compared
with peripheral blood stem cells for haploidentical transplantationwith a nonmyeloablative conditioning regimen and post-
transplantation cyclophosphamide. Biol Blood Marrow Transplant.
2014;20:724-729.
38. Gayoso J, Balsalobre P, Castilla-Llorente C, et al. Haploidentical stem
cell transplantation (HAPLO-HSCT) with reduced intensity condition-
ing (RIC) regimens and high dose cylophosphamide post-transplant
(HD-CY) as GVHD prophylaxis in patients with relapsed or refractory
Hodgkin’s disease: multicentric Spanish experience. Blood. 2013;122:
3406.
39. Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone
marrow transplantation with posttransplant cyclophosphamide
expands the donor pool for patients with sickle cell disease. Blood.
2012;120:4285-4291.
40. Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophos-
phamide as single-agent, short-course prophylaxis of graft-versus-host
disease. Blood. 2010;115:3224-3230.
41. Kanakry CG, O’Donnell P, Furlong T, et al. Post-transplantation cyclo-
phosphamide following busulfan and ﬂudarabine myeloablative
conditioning prevents severe acute and chronic graft-versus-host
disease and minimizes duration of immunosuppression: results of a
multi-institutional trial in patients with high-risk hematologic malig-
nancies. Blood. 2013;122:3310.
42. Alousi AM, Saliba RM, Chen J, et al. A matched controlled analysis of
post-transplant cyclophosphamide (CY) versus tacrolimus and mini-
dose methotrexate in matched sibling and unrelated donor
transplant recipients receiving reduced-intensity conditioning: post-
transplant CY is associated with higher rates of acute GVHD. Blood.
2012;120:4200.
43. Heine A, Held SAE, Daecke SN, et al. The JAK-inhibitor impairs dendritic
cell function in vitro and in vivo. Blood. 2013;122:1192-1202.
44. Choi SW, Braun T, Chang L, et al. Vorinostat plus tacrolimus and
mycophenolate to prevent graft-versus-host disease after related-
donor reduced-intensity conditioning allogeneic haematopoietic
stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15:
87-95.
45. Dezern AE, Luznik L, Fuchs EJ, et al. Post-transplantation cyclophos-
phamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow
Transplant. 2011;46:1012-1013.
